Compare Eli Lilly And Co (LLY) vs Impinj Inc (PI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Impinj Inc — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while Impinj Inc trades at $189.55 (market cap $5.60B). The key difference: Eli Lilly And Co is far larger — about 185.7× Impinj Inc's market cap, and Eli Lilly And Co pays a 0.59% dividend while Impinj Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Impinj Inc for 22 Days on average.
| LLY | PI | |
|---|---|---|
Market Cap | $1.04T | $5.60B |
Volume | 3,064,878 | 9,929 |
Sector | Health | Technology |
52-Week High | $1.28K | $241.91 |
52-Week Low | $799.57 | $91.34 |
Typical Hold Time | 93 Days | 22 Days |
Enterprise Value | $1.09T | $5.73B |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company's weight-loss drug portfolio continues to drive exceptional performance, with Q2 2026 EPS of $8.38 beating expectations by 31%. Technical indicators show bullish moving averages while fundamentals reveal impressive 83.4% gross margins and 102.44% ROE. Recent clinical trial successes for next-generation obesity treatments position Lilly for continued market leadership.
LLY presents a compelling growth story with dominant positioning in the expanding obesity/diabetes market, though elevated valuations (P/E 39.26) and regulatory risks require monitoring. Analyst consensus remains strongly bullish with $1,350 price target representing 15% upside. The primary investment thesis centers on pipeline execution and market expansion opportunities, balanced against competitive pressures and valuation concerns.
Impinj (PI) trades at $183.37, down 4.01% today, with strong analyst support (16 Buy, 0 Sell) and a $178.83 consensus target. Recent Q2 2026 earnings beat expectations ($0.86 vs. $0.795), but the company remains unprofitable with a -7.26% net margin. Technical indicators show a bullish trend, with support at $181 and resistance at $188. The stock is positioned near its pivot point of $185 amid ongoing operational growth in RFID technology.
Outlook: PI offers growth potential in RFID markets, but profitability concerns and high valuations (P/S 14.83, EV/EBITDA 523.68) pose risks. Investors should weigh strong revenue trends against negative margins and monitor Q3 2026 results for sustained execution. Near-term price action may hinge on technical support levels and institutional sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Impinj Inc
Impinj, Inc. is a leading provider of RAIN RFID (radio-frequency identification) solutions. The company's platform includes endpoints (tag chips), connectivity devices (readers and gateways), and software, enabling businesses to wirelessly identify, locate, and authenticate everyday items. Impinj's technology is crucial for applications in retail, supply chain management, healthcare, and logistics, helping businesses to automate inventory, track assets, and improve operational efficiency.
Read more on PI →
